Generic drugs account for roughly 91% of all U.S. prescriptions filled while representing only about 18% of total drug spend. […]

A deep-dive reference for pharma/biotech IP teams, R&D leads, and institutional investors operating in or sourcing from the European market.

1. The Market Structure Forcing Manufacturing Innovation The global generic drug market generated approximately $245 billion in 2020 and is

1. The Strategic Stakes: Why Your CDMO Model Choice Determines IP Value, Not Just Cost The question most pharmaceutical executives

Introduction: The Strategic Imperative of Project Management in the Modern CDMO Ecosystem The pharmaceutical and biotechnology industries operate at the

Generic drug development is a precision game, not a volume game. The companies pulling consistent margin out of a commoditized

Generic drugs fill 91% of U.S. prescriptions but account for only 18% of total drug spending. That gap, roughly $400

A deep-dive reference for oral solid dosage strategy, patent lifecycle management, and formulation-based value creation. 1. The Multi-Unit Architecture: Why

Generic drug development runs on borrowed science. The molecule has already been discovered, the clinical benefit already proven. The scientific